 SAN FRANCISCO, July 07, 2020 GLOBE NEWSWIRE -- 89bio, Inc. Nasdaq: ETNB, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized underwritten public offering of 2,649,600 shares of its common stock at a public offering price of 27.50 per share. In addition, 89bio has granted the underwriters a 30-day option to purchase up to an additional 397,440 shares of common stock at the public offering price, less the underwriting discounts and commissions. BofA Securities, SVB Leerink and RBC Capital Markets are acting as joint book-running managers for the offering. 